html[data-identity='g1'] .g1-header .g1-header-wide .g1-header-layers button { display: none; } html[data-identity='g1'] .g1-header-wide .g1-header-layers a { align-self: center; } html[data-identity='g1'] .g1-header .g1-header-narrow { display: none; } html[data-identity='g1'] .g1-header-nojs { display: none; } @media (width < 721px) { html[data-identity='g1'] .g1-header .g1-header-nojs { display: flex; flex-wrap: wrap; column-gap: 20px; padding: 0 16px 8px; } html[data-identity='g1'] .g1-header-nojs ul { display: flex; gap: 20px; list-style: none; margin: 0; padding: 0; box-shadow: none; } html[data-identity='g1'] .g1-header-nojs a { display: block; padding: 6px 0; font-size: 15px; line-height: 24px; color: var(--ink2); text-decoration: none; } html[data-identity='g1'] .g1-header-nojs a[aria-current='true'] { color: var(--ink); text-decoration: underline 2px var(--ember); text-underline-offset: 6px; } }

PapersPMID:29696241

Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial.

Journal of the Endocrine Society2018The record ↗

findings: 4
compound: 1
endpoints: 4

O-acetyl-(R)-carnitine

PMID:29696241

no difference foundTriglycerides
no difference foundHDL cholesterol
no difference foundLDL cholesterol
no difference foundTotal cholesterol (TC)

Study, every finding: RCT · 6 months
Dose studied, every finding: acetyl-L-carnitine 1000 mg orally twice daily for 6 months
Population, every finding: Adults over 40 with type 2 diabetes, hypertension and dyslipidemia, all on simvastatin 10 to 20 mg/d in both arms; ALC 116 and placebo 113 randomised; 6 months

No finding here moved its endpoint.

What did not

How to read these marks →

“The effect of ALC on triglycerides, lipoprotein(a), LDL, HDL, and total cholesterol was not significantly different from that of placebo.”
- No detected effect on triglycerides
  moderate
- No detected effect on HDL cholesterol
  moderate
- No detected effect on LDL cholesterol
  moderate
- No detected effect on total cholesterol (TC)
  moderate

Study record

Design: randomised controlled trial
Species: human
Population: Hypertensive dyslipidemic type 2 diabetes patients on background simvastatin
Participants: 229
Comparator: placebo
Duration: 183 days
Endpoints measured: 63